Loading clinical trials...
Loading clinical trials...
This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated o...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT06340568 · Endometrial Cancer
NCT06952504 · Endometrial Cancer
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT06253494 · Endometrial Cancer, Cancer of Endometrium, and more
University of South Alabama / Mitchell Cancer Institute Univ South Alabama
Mobile, Alabama
St. Jude Heritage Medical Group St Jude
Fullerton, California
USC/Kenneth Norris Comprehensive Cancer Center USC 2
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions